Cost-effectiveness of nasal high-flow in children with acute hypoxaemic respiratory failure.
Brenda GannonDonna FranklinVinh VoFranz E BablAndreas SchiblerPublished in: Journal of paediatrics and child health (2024)
As first-line treatment, NHF is unlikely to be cost-effective compared with SOT, but for non-obstructive patients who required escalation in care (non-obstructive non-responder), NHF is likely to be cost-effective if willingness-to-pay per reduced hospital length of stay is more than A$10 000 per patient.
Keyphrases
- respiratory failure
- extracorporeal membrane oxygenation
- healthcare
- mechanical ventilation
- palliative care
- case report
- health insurance
- quality improvement
- acute respiratory distress syndrome
- open label
- affordable care act
- pain management
- adverse drug
- intensive care unit
- clinical trial
- emergency department
- chronic rhinosinusitis
- chronic pain
- study protocol